Granules India’s Jeedimetla facility completed the US FDA inspection

Granules India’s Jeedimetla facility completed the US FDA inspection

Jeedimetla facility manufactures Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFIs).

FPJ Web DeskUpdated: Friday, June 23, 2023, 03:42 PM IST
article-image
Granules India’s Jeedimetla facility completed the US FDA inspection | Image: Granules (Representative)

Granules Jeedimetla facility located at Hyderabad, Telangana, India has successfully completed the US FDA’s surveillance inspection with zero observations, the company announced through an exchange filing. The inspection was completed between June 19 and June 23.

Jeedimetla facility manufactures Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates (PFIs).

Granules shares

The shares of Granules on Friday closed at Rs 286.95, down by 0.35 per cent.

RECENT STORIES

Amazon India, Flipkart Must Remove Products Infringing Reliance, Jio Trademarks: Delhi High Court

Amazon India, Flipkart Must Remove Products Infringing Reliance, Jio Trademarks: Delhi High Court

India, EU To Hold Next Round Of Free Trade Agreement Talks In September

India, EU To Hold Next Round Of Free Trade Agreement Talks In September

ICICI Prudential Life Q1 FY26 Profit Falls 21.8% QoQ, Premium Income Drops 48%

ICICI Prudential Life Q1 FY26 Profit Falls 21.8% QoQ, Premium Income Drops 48%

Gold Dips By ₹200 To ₹99,370 Per 10g, Silver Drops Sharply By ₹3,000 To Rs 1.12 Lakh/Kg

Gold Dips By ₹200 To ₹99,370 Per 10g, Silver Drops Sharply By ₹3,000 To Rs 1.12 Lakh/Kg

Exports Steady At USD 35.14 Bn In June, Trade Deficit Narrows To 4-Month Low Of USD 18.78 Bn

Exports Steady At USD 35.14 Bn In June, Trade Deficit Narrows To 4-Month Low Of USD 18.78 Bn